These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35024891)

  • 1. Treatment with Soluble Activin Type IIB Receptor Ameliorates Ovariectomy-Induced Bone Loss and Fat Gain in Mice.
    Puolakkainen T; Rummukainen P; Pihala-Nieminen V; Ritvos O; Savontaus E; Kiviranta R
    Calcif Tissue Int; 2022 Apr; 110(4):504-517. PubMed ID: 35024891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
    Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
    BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble activin type IIB receptor improves fracture healing in a closed tibial fracture mouse model.
    Puolakkainen T; Rummukainen P; Lehto J; Ritvos O; Hiltunen A; Säämänen AM; Kiviranta R
    PLoS One; 2017; 12(7):e0180593. PubMed ID: 28704409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.
    Koncarevic A; Cornwall-Brady M; Pullen A; Davies M; Sako D; Liu J; Kumar R; Tomkinson K; Baker T; Umiker B; Monnell T; Grinberg AV; Liharska K; Underwood KW; Ucran JA; Howard E; Barberio J; Spaits M; Pearsall S; Seehra J; Lachey J
    Endocrinology; 2010 Sep; 151(9):4289-300. PubMed ID: 20573726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A myostatin and activin decoy receptor enhances bone formation in mice.
    Bialek P; Parkington J; Li X; Gavin D; Wallace C; Zhang J; Root A; Yan G; Warner L; Seeherman HJ; Yaworsky PJ
    Bone; 2014 Mar; 60():162-71. PubMed ID: 24333131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of PPARγ inhibition on bone marrow adipose tissue and bone in C3H/HeJ mice.
    Beekman KM; Veldhuis-Vlug AG; van der Veen A; den Heijer M; Maas M; Kerckhofs G; Parac-Vogt TN; Bisschop PH; Bravenboer N
    Am J Physiol Endocrinol Metab; 2019 Jan; 316(1):E96-E105. PubMed ID: 30457914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of substance P signaling aggravates the bone loss in ovariectomy-induced osteoporosis.
    Zheng XF; Zhao ED; He JY; Zhang YH; Jiang SD; Jiang LS
    Prog Biophys Mol Biol; 2016 Nov; 122(2):112-121. PubMed ID: 27237582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired bone healing pattern in mice with ovariectomy-induced osteoporosis: A drill-hole defect model.
    He YX; Zhang G; Pan XH; Liu Z; Zheng LZ; Chan CW; Lee KM; Cao YP; Li G; Wei L; Hung LK; Leung KS; Qin L
    Bone; 2011 Jun; 48(6):1388-400. PubMed ID: 21421090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel therapeutic approach to treating obesity through modulation of TGFβ signaling.
    Koncarevic A; Kajimura S; Cornwall-Brady M; Andreucci A; Pullen A; Sako D; Kumar R; Grinberg AV; Liharska K; Ucran JA; Howard E; Spiegelman BM; Seehra J; Lachey J
    Endocrinology; 2012 Jul; 153(7):3133-46. PubMed ID: 22549226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice.
    Cho SW; Sun HJ; Yang JY; Jung JY; An JH; Cho HY; Choi HJ; Kim SW; Kim SY; Kim D; Shin CS
    Mol Ther; 2009 Nov; 17(11):1979-87. PubMed ID: 19603006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.
    Rahimov F; King OD; Warsing LC; Powell RE; Emerson CP; Kunkel LM; Wagner KR
    Physiol Genomics; 2011 Apr; 43(8):398-407. PubMed ID: 21266502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimethyloxalylglycine prevents bone loss in ovariectomized C57BL/6J mice through enhanced angiogenesis and osteogenesis.
    Peng J; Lai ZG; Fang ZL; Xing S; Hui K; Hao C; Jin Q; Qi Z; Shen WJ; Dong QN; Bing ZH; Fu DL
    PLoS One; 2014; 9(11):e112744. PubMed ID: 25394221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marrow adipogenesis and bone loss that parallels estrogen deficiency is slowed by low-intensity mechanical signals.
    Krishnamoorthy D; Frechette DM; Adler BJ; Green DE; Chan ME; Rubin CT
    Osteoporos Int; 2016 Feb; 27(2):747-56. PubMed ID: 26323329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
    Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
    J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
    Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strain-dependent variations in the response of cancellous bone to ovariectomy in mice.
    Iwaniec UT; Yuan D; Power RA; Wronski TJ
    J Bone Miner Res; 2006 Jul; 21(7):1068-74. PubMed ID: 16813527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.
    Chiu CS; Peekhaus N; Weber H; Adamski S; Murray EM; Zhang HZ; Zhao JZ; Ernst R; Lineberger J; Huang L; Hampton R; Arnold BA; Vitelli S; Hamuro L; Wang WR; Wei N; Dillon GM; Miao J; Alves SE; Glantschnig H; Wang F; Wilkinson HA
    J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1181-92. PubMed ID: 23525481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
    Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of an activin receptor IIB ligand trap protects male juvenile rhesus macaques from simian immunodeficiency virus-associated bone loss.
    Guo W; Pencina KM; O'Connell K; Montano M; Peng L; Westmoreland S; Glowacki J; Bhasin S
    Bone; 2017 Apr; 97():209-215. PubMed ID: 28132908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.
    O'Connell KE; Guo W; Serra C; Beck M; Wachtman L; Hoggatt A; Xia D; Pearson C; Knight H; O'Connell M; Miller AD; Westmoreland SV; Bhasin S
    FASEB J; 2015 Apr; 29(4):1165-75. PubMed ID: 25466897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.